- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Celltrion to internalize U.S. production with $18B investment in New Jersey facility | 1 | Korea Joongang Daily | ||
| 14.01. | Celltrion heir outlines aggressive pipeline expansion at JPMorgan | 2 | Korea Herald | ||
| 14.01. | Celltrion Reveals Strategic Vision at JPM Conference | 3 | BusinessKorea | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 06.01. | Abpro And Celltrion Secure FDA Clearance For Lead Oncology Program, Stock Up | - | RTTNews | ||
| 06.01. | Abpro und Celltrion: FDA genehmigt klinische Studie für Therapie gegen solide Tumore | 1 | Investing.com Deutsch | ||
| 06.01. | FDA clears Abpro and Celltrion's solid tumor therapy for clinical trial | 1 | Investing.com | ||
| 06.01. | Celltrion opens first U.S. plant to anchor global supply chain | 2 | Korea Herald | ||
| 06.01. | Celltrion opens production site in New Jersey | 1 | Korea Times | ||
| 02.01. | Celltrion completes acquisition of U.S. Eli Lilly plant | 4 | Korea Herald | ||
| 02.01. | Celltrion Acquires Eli Lilly's U.S. Facility with 680 billion won CMO Contract | 13 | BusinessKorea | ||
| 02.01. | Celltrion completes acquisition of US biopharmaceutical plant | 1 | Korea Times | ||
| 02.01. | Celltrion completes acquisition of U.S. biopharmaceutical plant | 1 | Yonhap News | ||
| 31.12.25 | Celltrion Seen Topping 4 Tril. Won in Annual Revenue and 1 Tril. Won in OP This Year | 1 | BusinessKorea | ||
| 31.12.25 | Celltrion projects first-ever 1 tln-won annual operating profit for 2025 | 2 | Yonhap News | ||
| 31.12.25 | Celltrion forecasts 137% year-on-year growth in 2025 profits | 1 | Korea Times | ||
| 29.12.25 | Dividendenbekanntmachungen (29.12.2025) | 12.712 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| 22.12.25 | Celltrion launches biosimilar Stoboclo-Osenvelt in Europe | 1 | Yonhap News | ||
| 18.12.25 | Celltrion receives positive CHMP Opinion for SteQeyma (ustekinumab biosimilar) autoinjector | 1 | City A.M. | ||
| 18.12.25 | Celltrion, Inc.: Celltrion erhält positive CHMP-Stellungnahme für den SteQeyma (Ustekinumab-Biosimilar) Fertigpen | 459 | Business Wire | SteQeyma 45 mg und 90 mg Injektionslösung in einem Fertigpen erhält positive CHMP-Stellungnahme, die die subkutane Verabreichung bei Patienten mit Plaque-Psoriasis, Psoriasis-Arthritis (PsA)... ► Artikel lesen | |
| 18.12.25 | Celltrion, Inc.: Celltrion receives positive CHMP Opinion for SteQeyma (ustekinumab biosimilar) autoinjector | 482 | Business Wire | SteQeyma45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis... ► Artikel lesen |
1 2 3 4 5 Weiter >>
119 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,63 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,04 | 0,00 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| COGENT BIOSCIENCES | 37,860 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,220 | 0,00 % | JPMorgan reiterates Overweight rating on Vera Therapeutics stock | ||
| SUMMIT THERAPEUTICS | 16,560 | +0,42 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,960 | 0,00 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| NUVALENT | 106,01 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,590 | 0,00 % | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | ||
| ARCELLX | 68,55 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 9,605 | 0,00 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,000 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| CG ONCOLOGY | 53,30 | 0,00 % | What Analysts Are Saying About CG Oncology Stock | ||
| KINIKSA PHARMACEUTICALS | 43,200 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,02 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| ALUMIS | 26,310 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.